BioLineRx Ltd.
Business
BioLineRx Ltd. is a biopharmaceutical company developing and commercializing therapeutics in oncology and rare diseases. Its main products and programs include the FDA‑approved APHEXDA® (motixafortide) for stem‑cell mobilization, ongoing motixafortide oncology and rare disease development programs, and the topical device BL‑5010 for non‑surgical lesion removal. Its operations are organized around drug development, in‑licensing and partnering activities, supported by a U.S. subsidiary and third‑party CRO and manufacturing relationships. BioLineRx distributes and advances programs globally through direct development and regional licensing partners in the U.S., Asia and Europe.
Summary from filing dated 2025-03-31
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-2.03M |
| Total assets | $40.91M |
| Total liabilities | $17.56M |
| Stockholders' equity | — |
| Operating cash flow | — |